Pharmacokinetics and tolerability of a single inhaled dose of zanamivir in children

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 1, 2000, Pages 36-46

  Peng, Amy W ^c   Hussey, Elizabeth K ^c   Rosolowski, Bonnie ^a   Blumer, Jeffrey L ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c NONE

Author keywords

Children; Influenza; Pediatric; Pharmacokinetic; Zanamivir

Indexed keywords

ZANAMIVIR;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INFANT; INFLUENZA; MALE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE;

EID: 0033998478     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)88495-7     Document Type: Article

References (27)

1. 1. Glezen WP. Considerations of the risk of influenza in children and indications for prophylaxis. Rev Infect Dis. 1980;2:408-420.
2. 2. Ryan-Poirier K. Influenza virus infection in children. Adv Pediatr Infect Dis. 1995;10: 125-156.
3. 3. Glezen WP, Paredes A, Taber LH. Influenza in children. Relationship to other respiratory agents. JAMA. 1980;243:1345-1349.
4. 4. Kim HW, Brandt CD, Arrobio JO, et al. Influenza A and B virus infection in infants and young children during the years 1957-1976. Am J Epidemiol. 1979;109:464-479.
5. 5. Sugaya N, Nerome K, Ishida M, et al. Impact of influenza virus infection as a cause of pediatric hospitalization. J Infect Dis. 1992;165:373-375.
6. 6. Cate TR. Clinical manifestations and consequences of influenza. Am J Med. 1987;82:15-19.
7. 7. Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium [published correction appears in Antiviral Res. 1994;25:287]. Antiviral Res. 1994;25:123-131.
8. 8. Woods JM, Bethell RC, Coates JA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother. 1993;37:1473-1479.
9. 9. Thomas GP, Forsyth M, Penn CR, McCauley JW. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Res. 1994; 24:351-356.
10. 10. Ryan DM, Ticehurst J, Dempsey MH, Penn CR. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother. 1994;38:2270-2275.
11. 11. Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother. 1995;39:2583-2584.
12. 12. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307:580-584.
13. 13. Mossad SB. Underused options for preventing and treating influenza. Clevel Clin J Med. 1999;66:19-23.
14. 14. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997;337:874-880.
15. 15. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group [published correction appears in Lancet. 1999;353:504]. Lancet. 1998;352:1877-1881.
16. 16. Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA. 1996;275:295-299.
17. 17. Waghorn SL, Goa KL. Zanamivir. Drugs. 1998;55:721-725; discussion 725-727.
18. 18. Hayden F, Lobo M, Hussey E, Eason C. Efficacy of intranasal zanamivir in experimental human influenza A and B virus infection. In: Brown L, Hampson A, Webster A, eds. Options for Control of Influenza III. Amsterdam: Elsevier Science BV; 1996:718-725.
19. 19. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999;36(Suppl 1):1-11.
20. 20. Silagy CA. Treating influenza with zanamivir. Management of Influenza in the Southern Hemisphere Trialists. Lancet. 1999;353:669. Letter.
21. 21. Daniel MJ, Barnett JM, Pearson BA. The low potential for drug interactions with zanamivir. Clin Pharmacokinet. 1999;36(Suppl 1):41-50.
22. 22. Cass LM, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet. 1999;36(Suppl 1): 21-31.
23. 23. Peng AW, Stein DS, Gross C, et al. Sustained Concentration in Respiratory Tract after 10 mg Zanamivir (ZMV) Inhalation. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Calif: ASM Press; 1999:188 A/E 1921.
24. 24. Calfee DP, Hayden FG. New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs. 1998;56:537-553.
25. 25. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir in the treatment of symptomatic influenza A and B among children 5 to 12 years of age: A randomized controlled trial. Pediatr Infect Dis J. In press.
26. 26. Walker JB, Hussey EK, Treanor JJ, et al. Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J Infect Dis. 1997; 176:1417-1422.
27. 27. Heikkinen T, Ruuskanen O, Waris M, et al. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child. 1991;145:445-448.